news tech + games single source: Retraction Watch

Title: The Price of Progress: Inside the First Labor Fight at *The Lancet

Staff at The Lancet plan a strike over pay negotiations.

In a move signalling deep cracks under the surface of global academia, union members at The Lancet and its related journals are beginning their first-ever strike. Scheduled for September 22nd, this action follows months of deadlocked pay talks with parent publisher Elsevier. At heart, the conflict reflects a common pressure point: although these publications deliver essential scientific findings worldwide, their workforce argues that their salaries have dropped considerably compared to inflation, putting them "significantly poorer than they were five years prior."

The central issue rests on finances. Initially, the union sought a 7.5% increase in the first year. Elsevier offered substantially less: 4.1%, followed by 2.9%.

Given that 94.5% of covered employees voted for the strike, there was no moving forward path left available to both sides. Union organizers suggest Elsevier handled negotiations in a manner described as "very difficult and resistant," strengthening the union's stance on keeping its initial requests intact.

More than just walking out for one day, plans include implementing "work to rule" tactics from September 23rd through the 30th—doing exactly what contracts require but nothing more. This strategy intends to highlight plainly what workers perceive as dependence on unspoken favors—the assumption that staff regularly work extra shifts without payment purely because the institution needs it done regardless of contract terms.

This employment battle plays out amid huge profits generated by academic publishing corporations alike. As researchers seek fair remuneration matching staff input into science creation, Elsevier posted an adjusted operational income totaling $1.39 billion in 2025, achieving a strong profitability rate relative to similar companies ($38\%$).

Simultaneously, charges levied per processed article for The Lancet have almost doubled since late 2020 alone.

This situation transcends simple regional salary disagreements; it illustrates how organizational worth is divided when producing knowledge ties closely into investor payouts shared amongst shareholders. The clash inside The Lancet brings up major concerns about who ultimately reaps rewards—those conducting studies that advance our grasp of reality or those managing operations focused intensely on boosting earnings each quarter—especially when breakthrough discoveries rely upon committed individuals whose security feels constantly overlooked during valuation processes.*